EcoDrugPlus

60s Ribosomal Protein L21-Like

Ensembl ID : ENSPSNG00000005319
Gene Symbol: LOC116758076
2 Cross references
183 Possible Orthologues:

60s Ribosomal Protein L23-Like

Ensembl ID : ENSPSNG00000002992
Gene Symbol: LOC116751684
2 Cross references
206 Possible Orthologues:

60s Ribosomal Protein L30-Like

Ensembl ID : ENSPSNG00000007505
Gene Symbol: LOC116747271
2 Cross references
186 Possible Orthologues:

60s Ribosomal Protein L39-Like

Ensembl ID : ENSPSNG00000019858
Gene Symbol: LOC116762884
2 Cross references
68 Possible Orthologues:

60s Ribosomal Protein L9-Like

Ensembl ID : ENSPSNG00000015170
Gene Symbol: LOC116752754
2 Cross references
196 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPSNG00000020741
Gene Symbol: ARAF
3 Cross references
190 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSPSNG00000012102
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSPSNG00000022548
Gene Symbol: ADAM17
3 Cross references
282 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSPSNG00000015026
Gene Symbol: ADAMTS5
3 Cross references
200 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSPSNG00000013077
Gene Symbol: ADRM1
3 Cross references
255 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSPSNG00000015962
Gene Symbol: AKT1
3 Cross references
213 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSPSNG00000020140
Gene Symbol: AKT2
3 Cross references
253 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).